Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0396 | 0.8856 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0194 | 0.3657 | 0.3657 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0396 | 0.8856 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0168 | 0.2964 | 0.2964 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0145 | 0.2373 | 0.1794 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.626 | 0.626 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0145 | 0.2373 | 0.4505 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0319 | 0.6875 | 1 |
Echinococcus multilocularis | suppression of tumorigenicity 18 protein | 0.006 | 0.0189 | 0.0189 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.044 | 1 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.044 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0168 | 0.2964 | 0.2964 |
Echinococcus granulosus | histone acetyltransferase MYST2 | 0.006 | 0.0189 | 0.0189 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.044 | 1 | 1 |
Echinococcus granulosus | geminin | 0.0168 | 0.2964 | 0.2964 |
Brugia malayi | C2-HC type zinc finger protein C.e-MyT1 | 0.006 | 0.0189 | 0.0189 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0223 | 0.4406 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0319 | 0.6875 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0239 | 0.4801 | 1 |
Echinococcus multilocularis | endonuclease exonuclease phosphatase | 0.0212 | 0.4119 | 0.4119 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0145 | 0.2373 | 0.4505 |
Giardia lamblia | DNA topoisomerase II | 0.0421 | 0.9498 | 0.5 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.044 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0194 | 0.3657 | 0.3657 |
Schistosoma mansoni | hypothetical protein | 0.0326 | 0.7044 | 0.7044 |
Schistosoma mansoni | hypothetical protein | 0.0168 | 0.2964 | 0.2964 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0223 | 0.4406 | 0.3982 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0223 | 0.4406 | 0.3982 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0145 | 0.2373 | 0.4505 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.0189 | 0.0189 |
Echinococcus multilocularis | histone acetyltransferase MYST2 | 0.006 | 0.0189 | 0.0189 |
Leishmania major | DNA topoisomerase ii | 0.0396 | 0.8856 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.1061 | 0.1061 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.044 | 1 | 1 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0145 | 0.2373 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0223 | 0.4406 | 1 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0223 | 0.4406 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0396 | 0.8856 | 1 |
Brugia malayi | Probable DNA topoisomerase II | 0.044 | 1 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0319 | 0.6875 | 1 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0223 | 0.4406 | 0.3982 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.044 | 1 | 1 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0223 | 0.4406 | 0.9036 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0145 | 0.2373 | 0.1794 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.626 | 0.626 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0223 | 0.4406 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0145 | 0.2373 | 0.1794 |
Schistosoma mansoni | myelin transcription factor 1 myt1 | 0.006 | 0.0189 | 0.0189 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.044 | 1 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0145 | 0.2373 | 0.407 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.044 | 1 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.044 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.1061 | 0.1061 |
Loa Loa (eye worm) | MBCTL1 | 0.006 | 0.0189 | 0.0189 |
Echinococcus granulosus | endonuclease exonuclease phosphatase | 0.0212 | 0.4119 | 0.4119 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.1061 | 0.1061 |
Echinococcus granulosus | suppression of tumorigenicity 18 protein | 0.006 | 0.0189 | 0.0189 |
Schistosoma mansoni | DNA topoisomerase II | 0.044 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0396 | 0.8856 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 255 nM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
IC50 (binding) | = 255 nM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
IC50 (binding) | = 2100 nM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
IC50 (binding) | = 2100 nM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
IC50 (binding) | = 0.39 uM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
IC50 (binding) | = 0.39 uM | Inhibition of Mycobacterium tuberculosis InhA | ChEMBL. | 17034137 |
Inhibition (binding) | 0 | Inhibition of Mycobacterium tuberculosis InhA at 1.5 uM | ChEMBL. | 17034137 |
Inhibition (binding) | = 97 % | Inhibition of Mycobacterium tuberculosis InhA at 15 uM | ChEMBL. | 17034137 |
Inhibition (binding) | = 97 % | Inhibition of Mycobacterium tuberculosis InhA at 15 uM | ChEMBL. | 17034137 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.